GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

Many people stop taking GLP-1 drugs like Ozempic within a year, but doing so often leads to weight regain. Here's what to know before stopping.

What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

The most common GLP-1 drugs are Ozempic, Wegovy, Zepbound, and Mounjaro. There is currently no cure for macular degeneration, and it can lead to permanent vision loss or blindness.

If you have a history of gallbladder disease, you should not take GLP-1 agonists. Ozempic and Wegovy, both of which are GLP-1 agonists, can also result in vision changes.

Some consumers are taking smaller than standard doses of GLP-1s—the popular class of weight-loss and diabetes drugs that include Ozempic, Wegovy, and Zepbound—or spacing out doses longer than ...